Stock listing
A40D7P Stock Price, News, Filings & Events — Bioage Labs, Inc.
Selected listing: A40D7P · LS · EUR · DE
This page tracks Bioage Labs, Inc.'s A40D7P:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A40D7P:LS. A40D7P:LS is the stock-level entry point for investors researching Bioage Labs, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A40D7P:LS
- Asset type
- Stock
- Market cap
- $1.10B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Bioage Labs, Inc. A40D7P:LS stock context
This page tracks Bioage Labs, Inc.'s A40D7P:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A40D7P:LS. A40D7P:LS is the stock-level entry point for investors researching Bioage Labs, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Bioage Labs, Inc.
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular...
September 8, 2026
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Redu...
July 14, 2026
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in ...
June 16, 2026
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
May 8, 2026
Research Bioage Labs, Inc.
Bioage Labs, Inc. investor report
Review AI stock analysis and investor report context for A40D7P:LS.
Bioage Labs, Inc. company profile
View the public company page for Bioage Labs, Inc. on 6ix.
Bioage Labs, Inc. news
Read company news and market updates connected to Bioage Labs, Inc..
Bioage Labs, Inc. investor events
Find investor webinars, events, and replay context for Bioage Labs, Inc..
Alternate listings
BIOA:NASDAQ
US · USD
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:GETTEX
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
BIOA:BOATS
US · USD
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:TRADEGATE
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
A40D7P:LSX
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:FWB
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:DUS
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:HAM
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:MUN
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.
Y7G:SWB
DE · EUR
Alternate listing for Bioage Labs, Inc.; the primary context on this page is A40D7P:LS.